RE:RE:RE:RE:RE:Well We Will Soon Know Won’t WeOf course I remember that one, beenthere. It was a Christmas parlour game based on Bioasis's guidance that fall.
But it wasn't started by me.
And my entry to the contest was "18 and 4, maybe even more".
What readers here will remember and you cynically ignore is that I always accompanied that guess with the statement, "...if Bioasis does enough to be covered by the biotech and financial media, maybe even the popular media."
Of course, Bioasis has never accomplished that.
I'll stick with those predictions with the same caveats. There is no reason that I know of that would prevent the value of Bioasis from approaching the value of Denali if Bioasis gets xB3 results and deals that are competitive with Denali's, eventualities that certainly would be covered by the biotech and financial media, maybe even the popular media.
If Bioasis had begun a serious clinical program when the peptide was announced, or even earlier when MedImmune was doing its work with the peptide in 2013/14, then accomplishment and media coverage would have already happened and you could brag that you knew all along that it all would turn out this well.
I purposely added the caveats that deals and a high share price can't happen without accomplishment. I've been dead-on accurate with my "18 and 4" prediction.
Bioasis will never be in the news unless and until it does something big enough to make the news. That's how it works.
Thanks for this opportunity, beenthere.
jd